|
 |
· Case #1: 45-year-old premenopausal
woman with recurrent breast cancer who participated
in the trastuzumab pivotal trial |
| |
· Postmastectomy radiation therapy |
| |
· Choice of systemic therapy for patients
with HER2-positive metastatic disease |
| |
· Neoadjuvant trastuzumab |
| |
· Recent trastuzumab trials |
| |
· Clinical implications of the ATAC trial
results |
| |
· Fulvestrant: Sequencing of hormonal therapy
in metastatic disease |
| |
Select publications |
| |
|
· Case #2: 72-year-old woman with ER/PR-positive,
HER2-positive
breast cancer |
| |
· Selection of adjuvant therapy for high-risk
elderly patients |
| |
· Hormone therapy versus chemotherapy for
women with metastatic breast cancer |
| |
· Trastuzumab in elderly women |
| |
· Chemotherapy selection for patients with
metastatic breast cancer: Role of capecitabine |
| |
· Adjuvant chemotherapy for elderly women |
| |
· CALGB: Adjuvant trial of capecitabine
versus CA/CMF |
| |
Select publications |
| |
|
|
· 2002 ASCO technology assessment on the
use of adjuvant aromatase inhibitors |
| |
· Adjuvant therapy in ER-positive, HER2-positive
elderly patients with positive lymph nodes |
| |
· BCIRG trial of TAC versus FAC |
| |
· Sequencing of therapy for metastatic
ER-positive, HER2-positive breast cancer |
| |
· HER2-positive, estrogen receptor-negative
inflammatory breast cancer in an elderly patient |
| |
· Controversy regarding sentinel node examination |
| |
Select publications |
| |
|
|
· 2002 ASCO technology assessment of pharmacologic
interventions for breast cancer risk reduction including
tamoxifen, raloxifene, and aromatase inhibition |
| |
· Clinical implications of 2002 ASCO technology
assessment |
| |
· IBIS-2 chemoprevention trial |
| |
· Tamoxifen and the risk of uterine sarcoma |
| |
· Hormonal therapy and cognition |
| |
· Effects of tamoxifen on brain metabolism |
| |
· The role of lifestyle modifications in
breast cancer prevention |
| |
Select publications |
| |
|
Breast Cancer Update: A
CME Audio Series and Activity
Faculty Financial:
Interest or Affiliations
|
|
|
|
